$1.00
0.00% day before yesterday
Nasdaq, Nov 14, 09:00 pm CET
ISIN
US4976341051
Symbol
KRBP
Sector
Industry

Kiromic BioPharma Inc Stock price

$1.00
-0.06 5.88% 1M
-1.76 63.77% 6M
+0.13 14.94% YTD
+0.75 300.00% 1Y
-92.30 98.93% 3Y
-359.00 99.72% 5Y
-359.00 99.72% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
+0.00 0.00%
ISIN
US4976341051
Symbol
KRBP
Sector
Industry

Key metrics

Market capitalization $1.55m
Enterprise Value $13.20m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-23.39m
Free Cash Flow (TTM) Free Cash Flow $-21.66m
Cash position $3.06m
EPS (TTM) EPS $-21.61
Short interest 6.82%
Show more

Is Kiromic BioPharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Financial data from Kiromic BioPharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 2.80 2.80
1% 1%
-
-2.80 -2.80
1% 1%
-
- Selling and Administrative Expenses 3.50 3.50
41% 41%
-
- Research and Development Expense 14 14
42% 42%
-
-21 -21
10% 10%
-
- Depreciation and Amortization 2.80 2.80
1% 1%
-
EBIT (Operating Income) EBIT -23 -23
9% 9%
-
Net Profit -25 -25
7% 7%
-

In millions USD.

Don't miss a Thing! We will send you all news about Kiromic BioPharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kiromic BioPharma Inc Stock News

Neutral
Business Wire
about one month ago
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable ongoing efficacy results from follow-up visits for Patient 4 and Patient 6 in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small...
Neutral
Business Wire
about 2 months ago
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announces that the University of Arizona Cancer Center (UACC) has been activated as the fifth clinical trial site in the Deltacel-01 Phase 1 trial evaluating Deltacel™ (KB-GDT-01), Kiromic's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell l...
Neutral
Business Wire
about 2 months ago
HOUSTON--(BUSINESS WIRE)--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) announced today that the Deltacel-01 Safety Monitoring Committee (SMC) has unanimously voted in favor of proceeding with the expansion phase of the Deltacel-01 clinical trial. This trial is evaluating Deltacel™ (KB-GDT-01), the Company's allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in pa...
More Kiromic BioPharma Inc News

Company Profile

Kiromic Biopharma, Inc. operates as a biotechnology company, which engages in the development of cancer engineered immunotherapies. Its technologies include Intelligent Immunotherapy, Diamond AI, CancerSplice, ABBIE, and CAR-T Proprietary Binder Technology. The company was founded by Maurizio Chiriva-Internati and Scott Dahlbeck on August 6, 2006 and is headquartered in Houston, TX.

Head office United States
CEO Pietro Bersani
Employees 35
Founded 2006
Website www.kiromic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today